anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aimed to develop a computed tomography (CT)-based radiomics model capable of precisely predicting hyperprogression and pseudoprogression (PP) in patients with non-small cell lung cancer (NSCLC) treated with immunotherapy. We retrospectively analyzed 105 patients with NSCLC, from three institutions, treated with immune checkpoint inhibitors (ICIs) and categorized them into training and independent testing set. Subsequently, we processed CT scans with a series of image-preprocessing techniques, and 6008 radiomic features capturing intra- and peritumoral texture patterns were extracted. We used the least absolute shrinkage and selection operator logistic regression model to select radiomic features and construct machine learning models. To further differentiate between progressive disease (PD) and hyperprogressive disease (HPD), we developed a new radiomics model. The logistic regression (LR) model showed optimal performance in distinguishing PP from HPD, with areas under the receiver operating characteristic curve (AUC) of 0.95 (95% confidence interval [CI]: 0.91-0.99) and 0.88 (95% CI: 0.66-1) in the training and testing sets, respectively. Additionally, the support vector machine model showed optimal performance in distinguishing PD from HPD, with AUC of 0.97 (95% CI: 0.93-1) and 0.87 (95% CI: 0.72-1) in the training and testing sets, respectively. Kaplan‒Meier survival curves showed clear stratification between PP predicted by the radiomics model and true progression (HPD and PD) (hazard ratio = 0.337, 95% CI: 0.200-0.568, p < 0.01) in overall survival. Our study demonstrates that radiomic features extracted from baseline CT scans are effective in predicting PP and HPD in patients with NSCLC treated with ICIs.
BACKGROUND: Endovascular therapy (EVT) with devices such as drug-coated balloons (DCBs) and drug-eluting stents (DESs) for atherosclerotic disease in the femoropopliteal (FP) artery has been established. However, EVT using drug-based devices for chronic limb-threatening ischemia (CLTI) remains challenging. The optimal device for FP lesions in patients with CLTI remains unknown. This study compared the clinical efficacy of DCB and DES in patients with CLTI and FP lesions.
METHODS AND RESULTS: This retrospective single-center study included 539 consecutive patients (562 lesions) treated with EVT between January 2018 and December 2022; 166 patients with CLTI and Rutherford Class 5 or 6 wounds underwent EVT with DCB or DES. Clinical outcomes were compared between 53 pairs after propensity score matching. There were no significant differences between the DCB and DES groups in the incidence of complete wound healing without death or major amputation (84.8% vs. 80.2%, respectively; P=0.99), primary patency (69.4% vs. 75.6%, respectively; P=0.65), and freedom from target lesion revascularization at 1 year (78.6% vs. 78.0%, respectively; P=0.92). Multivariate analysis showed that complete wound healing at 1 year is negatively associated with hemodialysis and Wound, Ischemia, and foot Infection Stage 4, but positively associated with Global Limb Anatomic Staging System FP Grade 3 or 4.
CONCLUSIONS: No significant differences in clinical outcomes were found between DCB and DES for patients with CLTI and FP lesions.
PURPOSE:To obtain a colon cancer suppressing substance by using a water- soluble polysaccharide as an active component. CONSTITUTION:The objective substance contains a water-soluble polysaccharide originated from cereal, especially arabinoxylan as an active component. The water-soluble polysaccharide can be produced by treating the sugar, bran or hull of cereals with amylase to decompose and remove starch, extracting the residue with an aqueous solution of a harmless bivalent metal compound [e.g. aqueous solution of Ca(OH)2] and removing hemicellulose A fraction and proteins from the extract to collect a fraction having a molecular weight of >=100,000. The aqueous solution of the water-soluble polysaccharide is orally administered in the form of aqueous solution or spray-dried powder or by adding to a food or drink such as cooked rice, noodle or juice. The aqueous solution may be used as a drinkable preparation and the dried powder may be used as granules, tablet, capsule, etc., for oral administration.
A method of diagnosing exposure to a toxic agent comprising the steps of detecting the amount of protein/gene expression present in a sample of mammalian tissue or mammalian body fluids that has not been exposed to a toxic agent. Then the amount of protein/gene expression present in a sample of mammalian tissue or mammalian body fluids that has been exposed to the toxic agent is detected. A determination of the difference in the detected amount of protein/gene expression between the exposed and unexposed samples is made. A comparison of the difference to a library of expected protein/gene expression for predetermined toxic agents is made. Finally, an evaluation is made whether the difference indicates the exposure to a particular toxic agent. A treatment method for administering a therapeutic agent which inhibits the mechanistic pathways necessary to maintain the progression of lethal shock is also disclosed.
FIELD: medicine. ^ SUBSTANCE: adenoviral hybrid vector contains the first chain of adenovirus containing sequence of the first inverted terminal repeat (ITR) and signal sequence for packaging of adenovirus, the first non-coding sequence of the filler; sequence corresponding to tissue-specific promoter; chain of cDNA derived from alphavirus, which sequence is partially complementary to alphavirus RNA, including encoding sequence, an exogenous gene under interest; polyadenylation sequence and sequence of the second inverted terminal repeat (ITR). Pharmaceutical compositions containing such adenoviral vector hybrid and their application are revealed as well. The declared group of inventions can be used in the method of transfer of genetic material into cell, in particular into tumor cell which preferably expresses alpha-fetoprotein (AFP), and its application for induction of immune response against foreign antigens. ^ EFFECT: increasing of efficiency of therapeutic genes administration. ^ 38 cl, 17 dwg
NEW MATERIAL:An ethanolamine shown by the formula I (R<1> and R<2> are H, or acyl derived from nicotinic acid, triene higher fatty acid, or pentaenoic acid). EXAMPLE:N-5,8,11,14,17-Eicosapentaenoyl-2-aminoethanol. USE:An inhibitor of blood platelet aggregation. Having strong inhibitory action on blood platelet aggregation, useful as a preventive for thrombosis such as especially myocardial infarction, cerebral infarct, etc. and also as a preventive for cancer metastasis. PREPARATION:For example, nicotinic acid, a triene higher fatty acid, or a pentaene higher fatty acid or its reactive derivative is condensed with ethanolamine in a solvent such as tetrahydrofuran, etc. in an argon atmosphere in the presence of a condensation agent such as ethyl chloroformate, etc. to give a compound shown by the formula I .
After screening, eligible participants will start the placebo baseline ambulatory phase (4 days). On day 5, they will be hospitalized for three to five days, to undergo a "baseline" 72-hour CFA determination under a controlled diet and using a stool marker to indicate the beginning and end of the controlled diet period, while they continue receiving placebo treatment. At the end of the placebo baseline phase, participants will be randomized to a "high dose followed by a low dose" or to a "low dose followed by a high dose" EUR-1008 (APT-1008) dose sequence and proceed to the first crossover (treatment) phase. Each crossover (treatment) phase will consist of a stabilization period for six days at home, followed by a hospitalization of three to five days to undergo a 72-hour CFA determination using a controlled diet and using a stool marker to indicate the beginning and end of the controlled diet period.

Participants will immediately proceed from the first crossover (treatment) phase to the second without a washout period or return-to-baseline period in between phases. Participants will be stabilized at home for 6 days. Any residual lipase from the prior treatment phase is likely to be a negligible influence on the subsequent CFA determination because participants will be taking the new dose level (high or low) for six days before the beginning of sample collection for a new CFA. This interval is more than enough time for the CFA to be reflective of only the new dose.
The effects of fenofibrate on serum triglycerides were studied in two randomized, double-blind, placebo-controlled clinical trials of 147 patients with hypertriglyceridemia. Patients were treated for eight weeks under protocols that differed only in that one entered patients with baseline TG levels of 500 to 1,500 mg/dL, and the other TG levels of 350 to 499 mg/dL. In patients with hypertriglyceridemia and normal cholesterolemia with or without hyperchylomicronemia, treatment with fenofibrate decreased primarily very low-density lipoprotein (VLDL) triglycerides and VLDL cholesterol. Treatment of patients with elevated triglycerides often results in an increase of LDL-C (See Table 5). 

The effect of Antara on serum triglycerides was studied in a double-blind, randomized, 3 arm parallel-group trial of 146 patients. The study population was comprised of 61% male and 39% female patients. Approximately 70% of patients had hypertension and 32% had diabetes. Patients were treated for eight weeks with either a formulation of Antara comparable to 90 mg taken once daily with meals, a formulation of Antara comparable to 90 mg taken once daily between meals, or placebo. Antara, whether taken with meals or between meals, had comparable effects on TG and all lipid parameters (See Table 6).
A patient support system with chest compression system and harness assembly with sensor system. The harness assembly secures shoulders and hips of the patient on a patient support surface during transport. A chest compression system is integrated into the harness assembly in a manner that provides chest compressions to the patient while the patient is secured on the patient support surface. The tension of the harness assembly is selectively adjusted and/or a fluid bladder may be selectively expanded. A controller is in communication with the chest compression system and controls operation of the chest compression system. The sensor system is integrated into the harness assembly and in communication with the controller. The chest compression system may be removable from the harness assembly via an adapter. The chest compression system may be integrated into the patient support apparatus to secure the patient to the patient support surface while providing chest compressions.
The invention discloses an intelligent assistive device adaptive decision making system and method, and relates to the field of intelligent rehabilitation. The intelligent assistive device adaptive decision-making method comprises a CBR reasoning step, an RBR reasoning step and a clinical correction step. The system comprises a knowledge base, a data acquisition module, a data processing module, a mixed reasoning module and a result processing module. The data acquisition module acquires original data and uploads the original data to a case base in a knowledge base of the cloud platform for storage and standby, and the original data are transmitted to the data preprocessing module; and the data preprocessing module divides the acquired original data into CBR reasoning basic data and RBR reasoning basic data according to the correlation and carries out preprocessing. The hybrid inference module is configured to perform the CBR inference step and the RBR inference step. And the result processing module displays the decision result of the assistive device adaptation scheme through an interface and updates the case base.
Nanopolystyrene (NP) and diclofenac (DCF) are common environmental contaminants in the aquatic ecosystem; therefore, the present study aimed to investigate the hepatotoxicity of NP and/or DCF exposure on aquatic organisms and the underlying mechanisms. Juvenile Mylopharyngodon piceus were used as a model organism to study the effects of NP and/or DCF exposure at environmentally relevant concentrations for 21 days. Subchronic exposure to NP and/or DCF resulted in liver histological damage. In the NP group, the presence of large lipid droplets was observed, whereas the DCF group exhibited marked hepatic sinusoidal dilatation accompanied by inflammation. Additionally, this exposure induced liver oxidative stress, as evidenced by the changes in several physiological parameters, including catalase (CAT), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), total antioxidant capacity (T-AOC), reactive oxygen species (ROS), and malondialdehyde (MDA). Integrated transcriptomic and metabolomic analysis was performed to further investigate the molecular mechanism underlying hepatotoxicity. Multi-omics analysis demonstrated, for the first time to our knowledge, that NP induced hepatic steatosis mainly through activating the glycerol-3-phosphate pathway and inhibiting VLDL assembly by targeting several key enzyme genes including GPAT, DGAT, ACSL, APOB, and MTTP. Furthermore, NP exposure disrupted arachidonic acid metabolism, which induced the release of inflammatory factors and inhibited the release of anti-inflammatory factors, ultimately causing liver inflammation in M. piceus. In contrast, DCF induced interleukin production and downregulated KLF2, causing hepatic sinusoidal dilatation with inflammation in juvenile M. piceus, which is consistent with the finding of JAK-STAT signaling pathway activation. In addition, the upregulated AMPK signaling pathway in the DCF group suggested perturbation of energy metabolism. Collectively, these findings provide novel insights into the molecular mechanism of the multiple hepatotoxicity endpoints of NP and/or DCF exposure in aquatic organisms.
* The recommended starting dosage of ZEPBOUND is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. 
  * After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose. 
  * The recommended maintenance dosages of ZEPBOUND in adults are 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly. 
  * Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (6.1) and Clinical Studies (14.1)]. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage. 
  * The maximum dosage of ZEPBOUND is 15 mg injected subcutaneously once weekly.
A system and a computer-implemented method is provided for displaying live medical images of a subject. It comprises receiving a reference medical image and a live medical image of the subject. The reference image contains at least one marked position. Angle and zoom characteristics of the reference image and the live image are obtained. The method further comprises checking whether the reference image and the live image align based on their angle and zoom characteristics. If the reference image and the live image align, the reference image and live image are displayed to the user and at least one guideline is overlaid on top of the reference image and the live image. The guideline crosses the at least one marked position on the reference image.
The invention discloses a gastrodia elata-ganoderma lucidum wine and a preparation method thereof. The invention belongs to health tonic wines for human drinking and especially relates to a health tonic wine prepared by using gastrodia elata and ganoderma lucidum extract concentrates as principal functional raw materials and a preparation thereof. Active ingredients of the health tonic wine are prepared from gastrodia elata, ganoderma lucidum, bighead atractylodes rhizome, ginseng, white poria, cornus pulp, salvia miltiorrhiza, liquorice, crystal sugar and pure grain liquor. The preparation method comprises the following steps: 1) decocting and extracting gastrodia elata, ganoderma lucidum, bighead atractylodes rhizome, ginseng and white poria, then concentrating, drying extract and crushing for later use; 2) mixing and crushing cornus pulp, salvia miltiorrhiza and liquorice into coarse granules and then percolating with Baijiu to obtain a percolated liquid for later use; 3) boiling and melting the crystal sugar for later use; 4) blending the pure grain liquor to a needed alcohol strength for later use; and 5) mixing and stirring the above materials, then standing for aging, filtering and bottling to obtain the gastrodia elata-ganoderma lucidum wine. The preparation method has the advantages of accurate active ingredient control during preparation, rational and scientific raw material compatibility, simple end product wine preparation and small end product color deviation and can be put into large-scale production conveniently. The gastrodia elata-ganoderma lucidum wine contains multiple amino acids, microelements and the like which are necessary for human bodies, so that the gastrodia elata-ganoderma lucidum wine is a nourishing health tonic wine with healthcare functions such as fatigue resistance and immune adjustment.
This article comprehensively reviews how cerebral hypoxia impacts the physiological state of neurons and dendritic spines through a series of molecular changes, and explores the causal relationship between these changes and neuronal functional impairment. As a severe pathological condition, cerebral hypoxia can significantly alter the morphology and function of neurons and dendritic spines. Specifically, dendritic spines, being the critical structures for neurons to receive information, undergo changes such as a reduction in number and morphological abnormalities under hypoxic conditions. These alterations further affect synaptic function, leading to neurotransmission disorders. This article delves into the roles of molecular pathways like MAPK, AMPA receptors, NMDA receptors, and BDNF in the hypoxia-induced changes in neurons and dendritic spines, and outlines current treatment strategies. Neurons are particularly sensitive to cerebral hypoxia, with their apical dendrites being vulnerable to damage, thereby affecting cognitive function. Additionally, astrocytes and microglia play an indispensable role in protecting neuronal and synaptic structures, regulating their normal functions, and contributing to the repair process following injury. These studies not only contribute to understanding the pathogenesis of related neurological diseases but also provide important insights for developing novel therapeutic strategies. Future research should further focus on the dynamic changes in neurons and dendritic spines under hypoxic conditions and their intrinsic connections with cognitive function.
Electroconvulsive therapy (ECT) pulse amplitude, which dictates the induced electric field (E-field) magnitude in the brain, is presently fixed at 800 or 900 milliamperes (mA) without clinical or scientific rationale. We have previously demonstrated that increased E-field strength improves ECT's antidepressant effect but worsens cognitive outcomes. Amplitude-determined seizure titration may reduce the E-field variability relative to fixed amplitude ECT. In this investigation, we assessed the relationships among amplitude-determined seizure-threshold (STa), E-field magnitude, and clinical outcomes in older adults (age range 50 to 80 years) with depression. Subjects received brain imaging, depression assessment, and neuropsychological assessment pre-, mid-, and post-ECT. STa was determined during the first treatment with a Soterix Medical 4×1 High Definition ECT Multi-channel Stimulation Interface (Investigation Device Exemption: G200123). Subsequent treatments were completed with right unilateral electrode placement (RUL) and 800 mA. We calculated Ebrain defined as the 90th percentile of E-field magnitude in the whole brain for RUL electrode placement. Twenty-nine subjects were included in the final analyses. Ebrain per unit electrode current, Ebrain/I, was associated with STa. STa was associated with antidepressant outcomes at the mid-ECT assessment and bitemporal electrode placement switch. Ebrain/I was associated with changes in category fluency with a large effect size. The relationship between STa and Ebrain/I extends work from preclinical models and provides a validation step for ECT E-field modeling. ECT with individualized amplitude based on E-field modeling or STa has the potential to enhance neuroscience-based ECT parameter selection and improve clinical outcomes.
This paper presents a solution that prioritises high privacy protection and improves communication throughput for predicting the risk of sexually transmissible infections/human immunodeficiency virus (STIs/HIV). The approach utilised Federated Learning (FL) to construct a model from multiple clinics and key stakeholders. FL ensured that only models were shared between clinics, minimising the risk of personal information leakage. Additionally, an algorithm was explored on the FL manager side to construct a global model that aligns with the communication status of the system. Our proposed method introduced Random Forest Federated Learning for assessing the risk of STIs/HIV, incorporating a flexible aggregation process that can be adjusted to accommodate the capacious communication system. Experimental results demonstrated the significant potential of a solution for estimating STIs/HIV risk. In comparison with recent studies, our approach yielded superior results in terms of AUC (0.97) and accuracy ( 93 %  ). Despite these promising findings, a limitation of the study lies in the experiment for man's data, due to the self-reported nature of the data and sensitive content. which may be subject to participant bias. Future research could check the performance of the proposed framework in partnership with high-risk populations (e.g., men who have sex with men) to provide a more comprehensive understanding of the proposed framework's impact and ultimately aim to improve health outcomes/health service optimisation.
Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with durvalumab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who complete the first dose of tremelimumab and demonstrate clinical benefit based upon radiographic tumor regression and/or other clinical response without progression for at least 6 cycles or 6 months on treatment, whichever is shorter, and subsequently have evidence of progressive disease during the durvalumab monotherapy portion may receive a repeat dose of tremelimumab at the next scheduled cycle of treatment with durvalumab per physician discretion.
These women maintain normal bone mineral density (BMD) levels, typically assessed using Dual-X-ray Absorptiometry (DXA). A T-score above -1.0 is considered normal.